Safety and Efficacy of Bendamustine-Rituximab in Treatment Naïve Symptomatic Follicular Lymphoma: An Institutional Analysis.
作者信息
Gogia Ajay, Kumar Sudhir, Kumar Lalit, Sharma Atul, Mallick Soumya
机构信息
Department of Medical Oncology, Room No 218, Branch, All India Institute of Medical Sciences, New Delhi, India.
Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
出版信息
Indian J Hematol Blood Transfus. 2021 Jan;37(1):169-170. doi: 10.1007/s12288-020-01294-9. Epub 2020 Jun 9.
Abstract
摘要
相似文献
1
Safety and Efficacy of Bendamustine-Rituximab in Treatment Naïve Symptomatic Follicular Lymphoma: An Institutional Analysis.苯达莫司汀-利妥昔单抗治疗初治有症状滤泡性淋巴瘤的安全性和有效性：一项机构分析。
Indian J Hematol Blood Transfus. 2021 Jan;37(1):169-170. doi: 10.1007/s12288-020-01294-9. Epub 2020 Jun 9.
2
Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study.苯达莫司汀-120 联合利妥昔单抗治疗复发或难治性滤泡性淋巴瘤：一项多中心 II 期研究。
Ann Hematol. 2019 Sep;98(9):2131-2138. doi: 10.1007/s00277-019-03750-7. Epub 2019 Jul 8.
3
Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study.苯达莫司汀和利妥昔单抗治疗低肿瘤负荷滤泡淋巴瘤老年患者。LYSA Ⅱ期 BRIEF 研究结果。
Br J Haematol. 2018 Oct;183(1):76-86. doi: 10.1111/bjh.15513. Epub 2018 Aug 16.
4
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).一项由意大利淋巴瘤基金会（FIL）开展的 II 期研究，在老年晚期滤泡淋巴瘤患者中采用利妥昔单抗、苯达莫司汀、米托蒽醌（R-BM）短程诱导，随后进行利妥昔单抗巩固治疗。
Br J Haematol. 2021 Apr;193(2):280-289. doi: 10.1111/bjh.17283. Epub 2021 Jan 21.
5
Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.在 GADOLIN Ⅲ期研究中，评估奥滨尤妥珠单抗在利妥昔单抗难治性滤泡淋巴瘤患者中的药代动力学、暴露量、疗效和安全性。
Br J Clin Pharmacol. 2019 Sep;85(9):1935-1945. doi: 10.1111/bcp.13974. Epub 2019 Jul 12.
6
Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma.澳大利亚非霍奇金淋巴瘤的一线治疗。第 1 部分：滤泡性淋巴瘤。
Intern Med J. 2019 Apr;49(4):422-433. doi: 10.1111/imj.14113.
7
Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.苯达莫司汀联合利妥昔单抗作为西班牙滤泡性淋巴瘤患者一线治疗方案的成本效益分析
Appl Health Econ Health Policy. 2016 Aug;14(4):465-477. doi: 10.1007/s40258-016-0243-4.
8
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.在 GALLIUM 研究中，奥滨尤妥珠单抗或利妥昔单抗联合化疗治疗初治滤泡性淋巴瘤：化疗对疗效和安全性的影响。
J Clin Oncol. 2018 Aug 10;36(23):2395-2404. doi: 10.1200/JCO.2017.76.8960. Epub 2018 Jun 1.
9
Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.一线采用苯达莫司汀-利妥昔单抗治疗滤泡淋巴瘤后维持利妥昔单抗或观察。
Br J Haematol. 2019 Feb;184(4):524-535. doi: 10.1111/bjh.15720. Epub 2018 Dec 21.
10
Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.苯达莫司汀联合利妥昔单抗对比 R-CHOP 一线治疗 3A 级滤泡性淋巴瘤患者：一项多中心回顾性研究的证据。
Oncologist. 2018 Apr;23(4):454-460. doi: 10.1634/theoncologist.2017-0037. Epub 2018 Jan 9.
引用本文的文献
1
Clinical Outcome of Patients Receiving Rituximab in Combination with Bendamustine in Indolent B-cell Lymphomas: A Single-center Institutional Study.利妥昔单抗联合苯达莫司汀治疗惰性B细胞淋巴瘤患者的临床结果：一项单中心机构研究
J Cancer Allied Spec. 2024 Aug 16;10(2):677. doi: 10.37029/jcas.v10i2.677. eCollection 2024.
2
Safety and Efficacy of Bendamustine and Rituximab (BR) Regimen in Indian Chronic Lymphocytic Leukaemia Patients.苯达莫司汀与利妥昔单抗（BR）方案治疗印度慢性淋巴细胞白血病患者的安全性和有效性
Indian J Hematol Blood Transfus. 2023 Jan;39(1):33-39. doi: 10.1007/s12288-022-01544-y. Epub 2022 May 27.
本文引用的文献
1
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.利妥昔单抗联合来那度胺治疗晚期未经治疗的滤泡性淋巴瘤。
N Engl J Med. 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104.
2
Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.苯达莫司汀联合利妥昔单抗对比 R-CHOP 一线治疗 3A 级滤泡性淋巴瘤患者：一项多中心回顾性研究的证据。
Oncologist. 2018 Apr;23(4):454-460. doi: 10.1634/theoncologist.2017-0037. Epub 2018 Jan 9.
3
Follicular lymphoma: an Institutional Analysis.滤泡性淋巴瘤：一项机构分析。
Asian Pac J Cancer Prev. 2017 Mar 1;18(3):681-685. doi: 10.22034/APJCP.2017.18.3.681.
4
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.来那度胺和利妥昔单抗用于未经治疗的惰性淋巴瘤的安全性及活性：一项开放标签的2期试验
Lancet Oncol. 2014 Nov;15(12):1311-8. doi: 10.1016/S1470-2045(14)70455-3. Epub 2014 Oct 15.
5
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.苯达莫司汀-利妥昔单抗或 R-CHOP/R-CVP 一线治疗惰性 NHL 或 MCL 的随机试验：BRIGHT 研究。
Blood. 2014 May 8;123(19):2944-52. doi: 10.1182/blood-2013-11-531327. Epub 2014 Mar 3.
6
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.苯达莫司汀联合利妥昔单抗与 CHOP 联合利妥昔单抗作为惰性和套细胞淋巴瘤患者一线治疗的比较：一项开放标签、多中心、随机、3 期非劣效性临床试验。
Lancet. 2013 Apr 6;381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2. Epub 2013 Feb 20.
7
Severe cutaneous interface drug eruption associated with bendamustine.与苯达莫司汀相关的严重皮肤界面药物疹
Dermatol Online J. 2010 Jul 15;16(7):1.
Zotero 插件